Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New

Hepatocellular carcinoma (HCC) is the most common primary liver tumour (80-90%) and represents more than 5.7% of all cancers. Although in recent years the therapeutic options for these patients have increased, clinical results are yet unsatisfactory and the prognosis remains dismal. Clinical or molecular criteria allowing a more accurate selection of patients are in fact largely lacking.

Intervento di Frey

Intervento di Frey

Caso clinico: Paziente di 25 anni con litiasi del dotto di Wirsung associato a pancreatite cronica complicata da dolori invalidanti postprandiali.

Intervento:svuotamento parenchimale cefalico con estrazione della litiasi e realizzazione di una anastomosi wirsungdigiunale su ansa ad «Y»

Decorso postoperatorio normale e rientro a domicilio in sesta giornata

Lettura consigliata: SURGICAL TREATMENT OF CHRONIC PANCREATITIS 

New Approaches in Locoregional Therapies for Hepatocellular Carcinoma

PURPOSE:

Hepatocellular carcinoma (HCC) represent actually the fifth most common cancer worldwide, with liver transplantation and hepatic resection who represent the standard of care of curative treatment. Unfortunately, not all patient could benefit of curative treatment. For such patients, locoregional or systemic therapies represent a valid option in order to achieve the best survival possible.